_________________
June 4, 2024 | ValGenesis Inc. announced the launch of VLMS 5.0, the new version of its flagship digital validation lifecycle management software poised to transform the industry's approach to digital transformation.
ValGenesis and Autocal have strengthened their capabilities to assist life sciences companies in India meet stringent regulatory requirements for quality and safety in drug development
A global science and technology company selected ValGenesis VLMS to digitize the computer system validation process across its manufacturing sites.
ValGenesis Inc., the market leader in enterprise validation lifecycle management systems (VLMS) will unveil the next version of VLMS and an enhanced portfolio of cutting-edge solutions at ValConnect 2024 Europe, its annual European user conference to be held in Lisbon, Portugal.
ValGenesis and Adryan have strengthened their capabilities to assist life sciences companies meet stringent ISO, FDA, and EU regulatory requirements for quality and safety in drug development and manufacturing.
DynaCompliance helps life sciences companies integrate the latest digital technologies and data-driven approaches into drug development, manufacturing, and validation processes, through comprehensive compliance and validation solutions.
A pioneer in scientific research for complex and devastating diseases, the company is advancing a pipeline of potential critical drug therapies across neurology, neuropsychiatry, specialized immunology, and rare diseases.
Billennium will implement and manage the entire range of ValGenesis products including ValGenesis VLMS, the industry standard digital validation platform for life sciences worldwide.
ValGenesis partners with Contrader to offer innovative digital solutions for life sciences in Italy, combining expertise in validation and ICT to support Industry 4.0 transformation.
A multinational biopharmaceutical company selected ValGenesis iRisk for implementing the ICH Q14 framework on PAT analytical methods across its global manufacturing sites.